DURHAM – Dermavant Sciences, a biopharma firm with an office at the American Tobacco Campus, is beefing up its management team with four additional hires.
They are:
- David Rubenstein, M.D., Ph.D., Chief Scientific Officer
- Richard Peterson, Chief Financial Officer
- Ariel Jasie, Chief Business & Strategy Officer
- Chris Van Tuyl, General Counsel
“I am delighted to welcome David, Ric, Ariel, and Chris to our team and we look forward to advancing the development of a promising treatment for hyperhidrosis,” said Dr. Jacqualyn A. Fouse, Executive Chair of Dermavant, which is based in Switzerland. “I’m proud of the progress we’ve made in building a diverse pipeline and I look forward to continuing to build Dermavant into the industry leader in medical dermatology.”
The firm has five drugs under development.
Rubenstein previously worked at GlaxoSmithKline Dermatology as Vice President, Discovery and Preclinical Development. He also has taught at UNC-Chapel Hill.
Peterson was CFO at Sienna Biopharmaceuticals. He also worked at Triangle-based Novan.
Jasie was Chief Business Officer at Codiak BioSciences.
Van Tuylworked at Sacks Tierney P.A. He is a Duke Law School graduate.
